Senses Disorder TRIZ Cases

A therapeutic regimen uses sequential synthetic retinal derivative doses to restore visual function in patients with endogenous retinoid deficiency.

Chlorine dioxide compositions treat ocular infections via oxidative destruction of microbial loads, eliminating antibiotic resistance risks.

Structural modifications of isoquinoline sulfonyl derivatives improve pharmacokinetic profiles while reducing hERG inhibition risks.

Heteroaryl inhibitors resolve selectivity trade-offs by targeting PAD4 while avoiding off-target effects on PAD2.

Formula I non-steroidal compounds modulate glucocorticoid receptors to treat inflammation while reducing systemic side effects.

Retinal-cortical assembloids merge distinct organoids to support elongated axon growth and enhance retinal ganglion cell survival.

Ophthalmic composition stabilizes latanoprost using polyoxyl 40 hydrogenated castor oil and sorbitol.

Formula I compounds selectively target TRPM8 receptors to treat disorders without significant side effects.

A bispecific antibody binds IL-1R1 and NLRP3 to facilitate internalization and inhibit inflammasome activation.

Neural progenitor cells resolve the contradiction between reliability and regenerative capacity in optic neuropathy therapy.

Antibodies targeting the D2D3 region of uPAR inhibit integrin interactions and tumor metastasis while enabling detection of occupied receptors.

Engineering the hinge region of a monovalent antibody prevents cross-linking while extending plasma residence time through FcRn interaction.

A nasal spray device delivers theophylline directly to the nasal epithelium using a controlled plume with specific droplet size distribution.

Lipid vehicles deliver 9-cis-retinyl esters to bypass retinoid cycle blockades and maintain visual function.

Novel boron-containing small molecules target the hinge region of ROCK kinases to modulate enzyme activity with high specificity.

Chemical integration of silicone and acrylate units prevents phase separation in hybrid pressure-sensitive adhesives for transdermal drug delivery.

HSF1-activating compounds trigger heat shock protein expression to clear misfolded proteins in neurodegenerative disease models.

Oral hydantoin derivatives modulate Kv3 channels to protect auditory circuits from acute noise exposure.

Oil-in-water emulsion breaks into separate phases upon tear dilution, reducing evaporation and extending duration of action.

Direct coupling of isoquinoline carboxylic acid with amino acid derivatives produces lifitegrast intermediates without protection steps.

Merges hyaluronic acid and arabinogalactan to treat dry eye by stabilizing tear film while inhibiting xanthine oxidase inflammation.

Antibodies selectively bind to the unique ER-alpha36 epitope to inhibit receptor activity and modulate disease functions.

PEGylated human monoclonal antibodies extend circulation half-life and serum stability to sustain GM-CSF neutralization potency.

Indole compounds bypass unstable growth factors by activating the PI3K/Akt/mTOR pathway, enhancing wound healing without immunogenic risk.

Composite biligand molecules utilize 1,4-disubstituted-1,2,3-triazole connections to maintain serum stability while achieving high detection precision.

N-acetyl cysteine mediates between aminoglycosides and hair cells, reducing ototoxicity while maintaining clinical efficacy against bacterial infections.

Modified cyclic peptide structures increase somatostatin receptor binding affinity and duration of action to treat metabolic disorders.

Structural modifications enable systemic administration of a selective ROCK2 inhibitor, resolving the trade-off between treatment efficacy and toxicity.

Targeting specific T1R2 residues enhances sweet taste perception while managing compound design complexity through local quality and parameter changes.

Differentiating mesenchymal stem cells with bFGF, PDGF, heregulin, and cAMP overcomes short half-life and low target concentrations of recombinant factors.

Hydrogen isotope-enriched 1,2,4-oxadiazole benzoic acid compounds promote ribosomal readthrough of premature stop codons.

A biodegradable capsular bag system releases therapeutic agents via diffusion and degradation to provide sustained intraocular drug delivery.

Chemical modifications prevent Dicer cleavage, resolving nuclease vulnerability while maintaining RNA interference activity.

Mineralocorticoid receptor antagonists accelerate skin and corneal wound closure by blocking mineralocorticoid signaling pathways.

Oral EPA and DHA therapy reduces retinal fluid volume, lowering intravitreal injection frequency and side effects.

Shellac-coated oral superoxide dismutase bypasses invasive intravitreal injections to inhibit choroidal neovascularization.

A genetic construct encoding TrkB and its agonist promotes nerve cell survival and regeneration.

Topical arylsulfonamide compounds lower retinal vascular permeability to treat macular edema without affecting systemic glycemia levels.

Pyrazolopyridazine compounds restore Clarin-1 protein trafficking to the plasma membrane, addressing Usher Syndrome defects.

Dual NEP and ECE-1 inhibitors prevent retinal ganglion cell apoptosis by regulating intraocular pressure and maintaining ocular blood flow.

A dual cell aggregate culture combines retinal pigment epithelium and photoreceptor cells to enhance therapeutic potential.

Ethanol-extracted Cordyceps militaris alleviates dry eye disease by enhancing tear film stability and reducing corneal epithelial injury.

Selective naphthalene derivatives modulate the EP4 receptor pathway to enhance therapeutic efficacy in pain management applications.

Non-peptidic 3,4-substituted piperidine compounds block the renin-angiotensin system upstream of chymase bypass, avoiding ACE inhibitor side effects like cough.

Existing inhibitors fail to target oxidized cross-linked lipofuscin. CLR01 binds these aggregates through host-guest interactions, enabling lysosomal clearance.